Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

COPD: Update Bulletin [June 2014]

Product Code:
596200271
Release Date:
June 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in  COPD: GlaxoSmithKline’s Anoro approved in Europe for the treatment of COPD

Highlights from this event update bulletin

  • GlaxoSmithKline’s Anoro approved in EU, but rapid uptake unlikely
  • Triple fixed-dose combinations may be the most convenient treatment option
  • Outcome of ongoing LAMA/LABA cardiovascular risk studies unlikely to change treatment practice
  • Relvar/Breo: SUMMIT trial recruitment completed, but clinical impact uncertain
  • Pessimism for GlaxoSmithKline’s mepolizumab since IL8 considered a better target
  • Growing interest in stem cell therapies
  • Incruse (umeclidinium) approved in US and EU, but is perceived as offering no benefits over Spiriva

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved